Anthem Biosciences
Anthem Biosciences, a leading biotechnology firm headquartered in India, has established itself as a key player in the life sciences industry since its inception in 2009. With a strong operational presence across various regions, the company focuses on providing innovative solutions in drug discovery, development, and manufacturing. Specialising in custom biologics, Anthem Biosciences offers a range of services, including monoclonal antibody development and protein expression systems. Their commitment to quality and efficiency sets them apart in a competitive market. Over the years, the company has achieved significant milestones, enhancing its reputation for excellence in biopharmaceutical services. Recognised for its cutting-edge technologies and robust client partnerships, Anthem Biosciences continues to drive advancements in the biotechnology sector, positioning itself as a trusted partner for pharmaceutical and biotech companies worldwide.
DitchCarbon Score
How does Anthem Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anthem Biosciences's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Anthem Biosciences's reported carbon emissions
Anthem Biosciences, headquartered in India, currently does not have available carbon emissions data for the most recent year. However, the company has made commitments towards climate action. Anthem Biosciences is classified as a committed organisation under the Science Based Targets initiative (SBTi), indicating their intention to establish near-term reduction targets, although specific targets have not yet been disclosed. As of now, Anthem Biosciences has not committed to a net-zero target. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, which is increasingly under pressure to address carbon emissions and sustainability practices. While specific emissions data is lacking, the commitment to the SBTi suggests a proactive approach to managing their environmental impact in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anthem Biosciences is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
